



Society for Immunotherapy of Cancer

555 East Wells St., Suite 1100
Milwaukee, WI 53202-3823
Phone: (414) 271-2456
Fax: (414) 276-3349
www.sitcancer.org

Media Contact:

Julia Schultz, Director of Communications
Email: jaschultz@sitcancer.org
Phone: (414) 271-2456

FOR IMMEDIATE RELEASE

May 31, 2019

The Society for Immunotherapy of Cancer Recognizes Cancer Immunotherapy Month™

MILWAUKEE — Throughout the month of June, SITC will recognize “Cancer Immunotherapy Month™” by highlighting 30 ways the organization is shaping the future of cancer immunotherapy through the society’s social media platforms. “Cancer Immunotherapy Month™” was started by the Cancer Research Institute in 2013, with the goal of raising awareness for cancer immunotherapy. SITC is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

“Cancer Immunotherapy Month™ is an ideal opportunity to recognize the important progress immunotherapy has made in improving outcomes for subsets of patients across many different types of cancer. The advances in treatment are truly remarkable but there is much work to be done,” said SITC President Mario Sznol, MD. “By highlighting our efforts, and the groundbreaking work of others in this very important month, we hope to continue raising awareness of the benefit that cancer immunotherapy can provide. We also hope to raise awareness of the importance of continued research to realize its full potential.”

SITC also provides a variety of informative, free resources to educate patients, clinicians and researchers about cancer immunotherapy. These resources take the form of live events and online tools, including:

- For patients: [Understanding Cancer Immunotherapy \(Fifth Edition\)](#): Developed specifically for newly diagnosed and restaged cancer patients and their caregivers, this online activity, outlines the basics about how the immune system works to fight cancer, the types of cancer immunotherapy treatment and clinical trials as a treatment option for cancer patients.
- For clinicians: [Basic Principles of Cancer Immunotherapy](#): SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with U.S. Food and Drug Administration (FDA)-approved cancer immunotherapy treatments. Written by world-recognized thought leaders in the field of cancer immunotherapy, this text provides thorough coverage of the toxicity and management of adverse events experienced during treatment with immune checkpoint inhibitors.
- For researchers: [Primer on Tumor Immunology and Cancer Immunotherapy™](#): Shared with an audience of researchers, these presentations from the society’s 33rd Annual Meeting (SITC 2018) are designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

-more-

Connect to SITC Social Media

[Twitter](#) • [Facebook](#) • [LinkedIn](#) • [YouTube](#)



Society for Immunotherapy of Cancer

555 East Wells St., Suite 1100
Milwaukee, WI 53202-3823
Phone: (414) 271-2456
Fax: (414) 276-3349
www.sitcancer.org

- For clinicians, students and patient advocates: [Advances in Cancer Immunotherapy™](#) (ACI) is comprised of CME-, CNE-, CPE- and MOC-accredited in-person meetings, webinars and interactive online courses presented by leading local authorities in tumor immunology and cancer immunotherapy. Free for healthcare professionals, students and patient advocates, these programs teach the latest in immunotherapy issues, treatment options and clinical implementation strategies.
- For scientists: SITC will host two timely, back-to-back workshops Sept. 4–6, 2019, in Houston, Texas, that will address critical challenges, facilitate innovative collaborations, and develop strategies to ensure continued momentum in the field of cancer immunotherapy. Registration to attend the workshops, which will focus on [cancer immune responsiveness](#) and [adoptive cellular therapies](#), [now open](#).

“For more than three decades, SITC has served as a major catalyst in spurring collaborations among researchers and clinicians that trigger breakthroughs in cancer immunotherapy,” said James P. Allison, PhD, 2018 Nobel Laureate. “As a proud SITC member of 18 years, I look forward to continuing support of the society’s mission of improving cancer patient outcomes by advancing the science, development and application of cancer immunotherapy.”

For more information, please visit SITC’s website at www.sitcancer.org.

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit www.sitcancer.org and follow us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

###

Connect to SITC Social Media

[Twitter](#) • [Facebook](#) • [LinkedIn](#) • [YouTube](#)